About us
About us
Objective measurement of neuromuscular function should be mandatory. The depth of block cannot be guessed, inferred, or “assessed” by subjective means, regardless of one’s vast clinical experience - in other words, we should always use objective monitoring technology to identify NMBAs (and for that matter, neostigmine) as either “friend or foe.”
Sorin J. Brull, MD, FCARCSI (Hon)
Anesthesiology. 2015 Jun;122(6):1183-1185
A world leader in the development of perioperative monitoring solutions
Acacia Designs is a clincal innovation company developing solutions to enable safer surgery. Our mission is to improve patient outcomes and safety by developing solutions that set new clinical standards of patient monitoring during surgery and in the Intensive Care Unit (ICU).
Every year more than 20 million patients are affected by post-operative complications related to anesthesia and premature extubation. Of these, more than a million patients suffer severe post-operative Critical Respiratory Events (CREs) after surgery. Many of these life-threatening and costly adverse events are related to inadequate intraoperative patient monitoring. CREs can lead to major morbidity and mortality, decreased patient satisfaction during recovery from anesthesia, and can cause excess cost and needless delays in postoperative recovery.
CREs and post-operative complications are most efficiently avoided by objectively and reliably determining when patients are able to breathe again after surgery without assistance (i.e., when tracheal intubation and mechanical ventilation are no longer necessary). Objective determination (measurement) of neuromuscular function is critical during recovery from general anesthesia to ensure patient safety.
Acacia has developed novel, patent pending solutions for monitoring patients undergoing anesthesia to determine when it is safe to wake up the patient and allow spontaneous breathing following surgery. Acacia has collaborated with Mayo Clinic to develop the products and holds an IP license. Mayo Clinic is the largest integrated and highest ranked nonprofit medical group practice in the world.
Acacia’s solutions are intended specifically to enable improved patient safety following the administration of paralytic drugs, also known as neuromuscular blocking agents (NMBAs). It is essential to monitor patients who receive NMBAs to ensure the correct NMBA dose and to determine when patients can be safely transferred from the operating room to the postoperative care unit. Objective monitoring of the effects of NMBAs has also shown to reduce the incidence of postoperative pulmonary complications as well as improve patient satisfaction and reduce hospital length of stay
Acacia was founded in January 2014 as an intellectual property company developing high-quality medical monitoring devices that are based on physiologic principles; the monitors are aimed at reducing CREs and post-operative complications, and they help minimize the transmission of infection between patients by utilizing single-use, disposable accessories. The solutions are developed to meet the clinical demand and follow established clinical guidelines.
The first portfolio of products have successfully passed Phase III clinical studies. Acacia Designs’ first global licensing Agreement was signed in 2014. In 2015, Acacia acquired US based T4Analytics LLC, a company founded in 2011 (more info here). The acquisition strengthened Acacia's IP portfolio, and secured global rights to the technology.
Acacia Designs is founded and run by internationally recognized, experienced leaders in the field of anesthesia and medical device development. Acacia was funded by US- and Sweden-based investors and was acquired by the Swesdish medical device company Senzime AB in May of 2016.
For more information or if your curious to join us on our mission, please contact Philip Siberg on philip@acaciadesigns.eu
